1. Home
  2. NGNE vs MBCN Comparison

NGNE vs MBCN Comparison

Compare NGNE & MBCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$18.42

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo Middlefield Banc Corp.

MBCN

Middlefield Banc Corp.

N/A

Current Price

$32.93

Market Cap

274.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
MBCN
Founded
2003
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
274.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
MBCN
Price
$18.42
$32.93
Analyst Decision
Strong Buy
Hold
Analyst Count
7
1
Target Price
$40.14
$35.00
AVG Volume (30 Days)
152.7K
15.1K
Earning Date
11-13-2025
01-23-2026
Dividend Yield
N/A
2.55%
EPS Growth
N/A
48.42
EPS
N/A
2.61
Revenue
N/A
$75,400,000.00
Revenue This Year
N/A
$19.98
Revenue Next Year
N/A
$7.42
P/E Ratio
N/A
$12.62
Revenue Growth
N/A
16.60
52 Week Low
$6.88
$22.74
52 Week High
$37.27
$37.68

Technical Indicators

Market Signals
Indicator
NGNE
MBCN
Relative Strength Index (RSI) 46.26 36.58
Support Level $18.12 $32.47
Resistance Level $20.44 $35.27
Average True Range (ATR) 1.23 0.73
MACD 0.24 -0.20
Stochastic Oscillator 51.13 0.74

Price Performance

Historical Comparison
NGNE
MBCN

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About MBCN Middlefield Banc Corp.

Middlefield Banc Corp is a bank holding company. It offers customers, banking services including checking, savings, negotiable order of withdrawal (NOW) accounts, money market accounts, time deposits, commercial loans, real estate loans, a variety of consumer loans, safe deposit facilities, and travelers' checks. It also provides online banking and bill payment services to individuals and online cash management services to business customers.

Share on Social Networks: